TVTX
Travere Therapeutics, Inc.$52.17+3.26 (+6.67%)Prev Close$48.91·MCap$4.55B·P/E—·Vol2.05M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
54
$37.06M
◆
Net Activity
Net Seller
$37.06M
●
Active Insiders
11
last 12 mo
Over the past 12 months, insider activity at Travere Therapeutics, Inc. (TVTX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 54 insider sales totaling $37.06M. The most recent insider transaction was by Coughlin Timothy (director), who sold $141.3K worth of shares on May 19, 2026. Travere Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $4.55B.
TVTX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 19, 2026 | Coughlin Timothy | director | Sell | 3,250 | $43.49 | $141.3K | 52,250 |
| May 6, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 22,500 | $43.95 | $988.9K | 432,886 |
| May 6, 2026 | Inrig Jula | officer: CHIEF MEDICAL OFFICER | Sell | 22,485 | $45.15 | $1.02M | 113,549 |
| May 6, 2026 | Meckler Jeffrey A | director | Sell | 8,000 | $45.00 | $360.0K | 87,500 |
| May 6, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 24,250 | $45.06 | $1.09M | 107,287 |
| May 6, 2026 | Baynes Roy D. | director | Sell | 4,500 | $46.65 | $209.9K | 37,500 |
| May 6, 2026 | Heerma Peter | officer: CHIEF COMMERCIAL OFFICER | Sell | 2,174 | $46.65 | $101.4K | 140,684 |
| May 6, 2026 | Cline Christopher R. | officer: CHIEF FINANCIAL OFFICER | Sell | 2,491 | $46.31 | $115.4K | 118,968 |
| May 6, 2026 | ROTE WILLIAM E. | officer: Chief Research Officer | Sell | 2,763 | $43.95 | $121.4K | 115,474 |
| May 4, 2026 | Baynes Roy D. | director | Sell | 9,750 | $44.22 | $431.1K | 37,500 |
| Apr 23, 2026 | ROTE WILLIAM E. | officer: Chief Research Officer | Sell | 9,100 | $39.09 | $355.7K | 113,987 |
| Apr 16, 2026 | Baynes Roy D. | director | Sell | 32,750 | $41.29 | $1.35M | 44,250-43% |
| Apr 16, 2026 | LYONS GARY A | director | Sell | 8,000 | $41.07 | $328.6K | 57,500 |
| Apr 16, 2026 | Calvin Sandra | officer: SVP, CHIEF ACCOUNTING OFFICER | Sell | 21,977 | $41.07 | $902.6K | 42,353-34% |
| Apr 15, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 51,500 | $41.29 | $2.13M | 119,211-30% |
| Apr 15, 2026 | Heerma Peter | officer: CHIEF COMMERCIAL OFFICER | Sell | 7,215 | $41.93 | $302.5K | 138,608 |
| Apr 15, 2026 | Inrig Jula | officer: CHIEF MEDICAL OFFICER | Sell | 8,233 | $42.01 | $345.9K | 112,491 |
| Apr 15, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 64,000 | $41.09 | $2.63M | 440,071 |
| Apr 15, 2026 | Cline Christopher R. | officer: CHIEF FINANCIAL OFFICER | Sell | 8,327 | $41.91 | $349.0K | 125,161 |
| Apr 7, 2026 | Baynes Roy D. | director | Sell | 10,000 | $33.00 | $330.0K | 37,500 |
| Apr 2, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 60,000 | $30.93 | $1.86M | 457,984 |
| Apr 2, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 10,000 | $30.00 | $300.0K | 105,211 |
| Mar 18, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 10,000 | $28.09 | $280.9K | 105,211 |
| Feb 24, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 60,000 | $30.10 | $1.81M | 432,886 |
| Feb 19, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 10,000 | $27.83 | $278.3K | 109,532 |
| Feb 17, 2026 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 10,000 | $27.83 | $278.3K | 0 |
| Feb 5, 2026 | Cline Christopher R. | officer: CHIEF FINANCIAL OFFICER | Sell | 1,745 | $32.19 | $56.2K | 111,336 |
| Feb 5, 2026 | Inrig Jula | officer: CHIEF MEDICAL OFFICER | Sell | 1,779 | $32.21 | $57.3K | 105,938 |
| Feb 5, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 2,994 | $32.18 | $96.4K | 105,720 |
| Feb 3, 2026 | Calvin Sandra | officer: SVP, CHIEF ACCOUNTING OFFICER | Sell | 4,333 | $32.12 | $139.2K | 49,080 |
| Feb 3, 2026 | Cline Christopher R. | officer: CHIEF FINANCIAL OFFICER | Sell | 7,242 | $32.12 | $232.6K | 112,971 |
| Feb 3, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 100,087 | $32.28 | $3.23M | 466,521 |
| Feb 3, 2026 | Heerma Peter | officer: CHIEF COMMERCIAL OFFICER | Sell | 7,310 | $32.12 | $234.8K | 131,823 |
| Feb 3, 2026 | Inrig Jula | officer: CHIEF MEDICAL OFFICER | Sell | 6,956 | $32.12 | $223.4K | 107,485 |
| Feb 3, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 7,175 | $32.12 | $230.5K | 108,205 |
| Feb 3, 2026 | ROTE WILLIAM E. | officer: Chief Research Officer | Sell | 12,446 | $32.87 | $409.1K | 109,087 |
| Jan 27, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 60,000 | $30.09 | $1.81M | 419,173 |
| Jan 21, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 10,000 | $27.34 | $273.4K | 90,270 |
| Jan 7, 2026 | Inrig Jula | officer: CHIEF MEDICAL OFFICER | Sell | 2,476 | $39.74 | $98.4K | 86,756 |
| Dec 29, 2025 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 7,402 | $40.00 | $296.1K | 38,233 |
| Dec 29, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 4,980 | $40.00 | $199.2K | 113,013 |
| Dec 29, 2025 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 15,000 | $42.00 | $630.0K | 88,787 |
| Dec 29, 2025 | ROTE WILLIAM E. | Chief Research Officer | Sell | 60,000 | $40.10 | $2.41M | 101,443-37% |
| Dec 16, 2025 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 2,910 | $36.00 | $104.8K | 45,635 |
| Dec 3, 2025 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 20,000 | $35.01 | $700.2K | 92,083 |
| Nov 6, 2025 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 67,115 | $36.00 | $2.42M | 48,545-58% |
| Nov 4, 2025 | Coughlin Timothy | Sell | 18,000 | $35.03 | $630.6K | 55,500 | |
| Nov 4, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 5,591 | $35.00 | $195.7K | 119,071 |
| Oct 30, 2025 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 120,000 | $30.32 | $3.64M | 419,173 |
| Oct 30, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 2,662 | $30.00 | $79.9K | 124,662 |
Showing 1–50 of 177
1 / 4
TVTX Insider Buying Activity
The following table shows recent insider purchases of Travere Therapeutics, Inc. (TVTX) stock reported via SEC Form 4 filings.
No insider buying activity found for TVTX in the last 12 months.
TVTX Insider Selling Activity
The following table shows recent insider sales of Travere Therapeutics, Inc. (TVTX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 19, 2026 | Coughlin Timothy | director | Sell | 3,250 | $43.49 | $141.3K | 52,250 |
| May 6, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 22,500 | $43.95 | $988.9K | 432,886 |
| May 6, 2026 | Inrig Jula | officer: CHIEF MEDICAL OFFICER | Sell | 22,485 | $45.15 | $1.02M | 113,549 |
| May 6, 2026 | Meckler Jeffrey A | director | Sell | 8,000 | $45.00 | $360.0K | 87,500 |
| May 6, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 24,250 | $45.06 | $1.09M | 107,287 |
| May 6, 2026 | Baynes Roy D. | director | Sell | 4,500 | $46.65 | $209.9K | 37,500 |
| May 6, 2026 | Heerma Peter | officer: CHIEF COMMERCIAL OFFICER | Sell | 2,174 | $46.65 | $101.4K | 140,684 |
| May 6, 2026 | Cline Christopher R. | officer: CHIEF FINANCIAL OFFICER | Sell | 2,491 | $46.31 | $115.4K | 118,968 |
| May 6, 2026 | ROTE WILLIAM E. | officer: Chief Research Officer | Sell | 2,763 | $43.95 | $121.4K | 115,474 |
| May 4, 2026 | Baynes Roy D. | director | Sell | 9,750 | $44.22 | $431.1K | 37,500 |
| Apr 23, 2026 | ROTE WILLIAM E. | officer: Chief Research Officer | Sell | 9,100 | $39.09 | $355.7K | 113,987 |
| Apr 16, 2026 | Baynes Roy D. | director | Sell | 32,750 | $41.29 | $1.35M | 44,250-43% |
| Apr 16, 2026 | LYONS GARY A | director | Sell | 8,000 | $41.07 | $328.6K | 57,500 |
| Apr 16, 2026 | Calvin Sandra | officer: SVP, CHIEF ACCOUNTING OFFICER | Sell | 21,977 | $41.07 | $902.6K | 42,353-34% |
| Apr 15, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 51,500 | $41.29 | $2.13M | 119,211-30% |
| Apr 15, 2026 | Heerma Peter | officer: CHIEF COMMERCIAL OFFICER | Sell | 7,215 | $41.93 | $302.5K | 138,608 |
| Apr 15, 2026 | Inrig Jula | officer: CHIEF MEDICAL OFFICER | Sell | 8,233 | $42.01 | $345.9K | 112,491 |
| Apr 15, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 64,000 | $41.09 | $2.63M | 440,071 |
| Apr 15, 2026 | Cline Christopher R. | officer: CHIEF FINANCIAL OFFICER | Sell | 8,327 | $41.91 | $349.0K | 125,161 |
| Apr 7, 2026 | Baynes Roy D. | director | Sell | 10,000 | $33.00 | $330.0K | 37,500 |
| Apr 2, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 60,000 | $30.93 | $1.86M | 457,984 |
| Apr 2, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 10,000 | $30.00 | $300.0K | 105,211 |
| Mar 18, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 10,000 | $28.09 | $280.9K | 105,211 |
| Feb 24, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 60,000 | $30.10 | $1.81M | 432,886 |
| Feb 19, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 10,000 | $27.83 | $278.3K | 109,532 |
| Feb 17, 2026 | REED ELIZABETH E | Chief Legal Officer and GC | Sell | 10,000 | $27.83 | $278.3K | 0 |
| Feb 5, 2026 | Cline Christopher R. | officer: CHIEF FINANCIAL OFFICER | Sell | 1,745 | $32.19 | $56.2K | 111,336 |
| Feb 5, 2026 | Inrig Jula | officer: CHIEF MEDICAL OFFICER | Sell | 1,779 | $32.21 | $57.3K | 105,938 |
| Feb 5, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 2,994 | $32.18 | $96.4K | 105,720 |
| Feb 3, 2026 | Calvin Sandra | officer: SVP, CHIEF ACCOUNTING OFFICER | Sell | 4,333 | $32.12 | $139.2K | 49,080 |
| Feb 3, 2026 | Cline Christopher R. | officer: CHIEF FINANCIAL OFFICER | Sell | 7,242 | $32.12 | $232.6K | 112,971 |
| Feb 3, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 100,087 | $32.28 | $3.23M | 466,521 |
| Feb 3, 2026 | Heerma Peter | officer: CHIEF COMMERCIAL OFFICER | Sell | 7,310 | $32.12 | $234.8K | 131,823 |
| Feb 3, 2026 | Inrig Jula | officer: CHIEF MEDICAL OFFICER | Sell | 6,956 | $32.12 | $223.4K | 107,485 |
| Feb 3, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 7,175 | $32.12 | $230.5K | 108,205 |
| Feb 3, 2026 | ROTE WILLIAM E. | officer: Chief Research Officer | Sell | 12,446 | $32.87 | $409.1K | 109,087 |
| Jan 27, 2026 | Dube Eric M | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 60,000 | $30.09 | $1.81M | 419,173 |
| Jan 21, 2026 | REED ELIZABETH E | officer: Chief Legal Officer and GC | Sell | 10,000 | $27.34 | $273.4K | 90,270 |
| Jan 7, 2026 | Inrig Jula | officer: CHIEF MEDICAL OFFICER | Sell | 2,476 | $39.74 | $98.4K | 86,756 |
| Dec 29, 2025 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 7,402 | $40.00 | $296.1K | 38,233 |
| Dec 29, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 4,980 | $40.00 | $199.2K | 113,013 |
| Dec 29, 2025 | Inrig Jula | CHIEF MEDICAL OFFICER | Sell | 15,000 | $42.00 | $630.0K | 88,787 |
| Dec 29, 2025 | ROTE WILLIAM E. | Chief Research Officer | Sell | 60,000 | $40.10 | $2.41M | 101,443-37% |
| Dec 16, 2025 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 2,910 | $36.00 | $104.8K | 45,635 |
| Dec 3, 2025 | Cline Christopher R. | CHIEF FINANCIAL OFFICER | Sell | 20,000 | $35.01 | $700.2K | 92,083 |
| Nov 6, 2025 | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | 67,115 | $36.00 | $2.42M | 48,545-58% |
| Nov 4, 2025 | Coughlin Timothy | Sell | 18,000 | $35.03 | $630.6K | 55,500 | |
| Nov 4, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 5,591 | $35.00 | $195.7K | 119,071 |
| Oct 30, 2025 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 120,000 | $30.32 | $3.64M | 419,173 |
| Oct 30, 2025 | Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | 2,662 | $30.00 | $79.9K | 124,662 |
TVTX Insiders
Similar Stocks to TVTX
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B